Post Market Registry Study of the Philips QuickClear Mechanical Thrombectomy System

NCT ID: NCT05928221

Last Updated: 2026-02-06

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 50 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-06-14
• Study Completion Date: 2026-07-31

Brief Summary

A post-market study of the QuickClear Mechanical Thrombectomy system used for the removal of acute Deep Vein Thrombosis (DVT) from the deep veins of legs in the setting of an office interventional suite.

Detailed Description

The QuickClear Mechanical Thrombectomy system will be used in accordance with the Instruction for Use (IFU) to remove acute, symptomatic occlusive common femoral, external iliac or common iliac DVT or occlusive above and below knee popliteal DVT in an office based interventional suite. The intent of this post-market observational study is to further assess long-term safety and effectiveness of patients treated with the QuickClear Mechanical Thrombectomy system and to assess the feasibility of performing deep vein thrombectomy procedures in the office interventional suite.

Conditions

Acute Deep Venous Thrombosis of Ileofemoral Vein

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Thrombectomy

removal of fresh soft emboli and thrombi from the vessels of the venous system

Intervention Type: DEVICE

Other Intervention Names

QuickClear Mechanical Thrombectomy system

Eligibility Criteria

Inclusion Criteria

1. Male or Non-Pregnant Female, age 18 to 89.

2. For females of reproductive potential: negative pregnancy test ≤ 7 days before the procedure, use of highly effective contraception (abstinence is acceptable) for 12 months after the study treatment.

3. Onset of acute DVT symptoms of 14 days or less in the target limb.

4. Ability to take oral medication and be willing to adhere to the prescribed anti- coagulant regiment.

5. Occlusive DVT (confirmed by either venous duplex ultrasound or CT venogram) spanning at least one of the following:

1. the iliac and/or common femoral vein. Extension into the femoral vein and/or profunda vein is allowed. OR

2. the entire popliteal vein (above and below knee). Extension into the femoral vein and/or tibial veins is allowed.

6. People who have scheduled or will be scheduled for treatment with the QuickClear Mechanical Thrombectomy system

7. Symptomatic DVT defined as meeting at least one of the following clinical indicators:

1. rVCSS Pain Score ≥2

2. New edema of calf or thigh (CEAP ≥3)

Exclusion Criteria

1. Non-ambulatory status prior to DVT occurrence.

2. Inability to lie in supine or prone under local anesthesia with moderate sedation for procedure.

3. In the contralateral (non-study) leg: symptomatic DVT that, in the operating physician's opinion, will require treatment in the following 30 days.

4. Critical limb ischemia with ulcer, gangrene, or rest pain (i.e., above symptoms or findings and ankle-brachial index <0.5, absolute ankle pressure <50 mm Hg or absolute toe pressure <30 mmHg).

5. Pulmonary embolism (PE) defined as either massive (systolic blood pressure < 90 mm Hg and/or patient on IV vasoactive medication to support blood pressure), or intermediate high-risk PE, as defined by the European Society Guideline on management of PE. Low-risk PE and/or intermediate low-risk PE can be enrolled.

6. Inability to tolerate contemporary venous intervention procedure due to severe dyspnea or acute systemic illness.

7. Allergy, hypersensitivity, or thrombocytopenia from heparin, iodinated contrast, except for mild-moderate contrast allergies for which steroid pre-medication can be used.

8. History of, or active heparin-induced thrombocytopenia (HIT).

9. Hemoglobin ≤9.0 mg/dl, INR>1.6 before starting anticoagulation, or platelets < 100,000/ml. Moderate renal impairment in diabetic patients (eGFR <60 ml/min) or severe renal impairment in non-diabetic patients (eGFR< 30 ml/min).

10. Active bleeding, recent (< 3 mo) GI bleeding, severe liver dysfunction, bleeding diathesis.

11. Recent (< 3 mo) internal eye surgery or hemorrhagic retinopathy; recent (<10 days) major surgery, cataract surgery, trauma, cardiopulmonary resuscitation, or other invasive procedure; or obstetrical delivery < 72 hours prior to procedure.

12. History of hemorrhagic stroke or intracranial/intraspinal bleed, tumor, vascular malformation, aneurysm.

13. Active cancer with a life expectancy of < 1 year.

14. Severe hypertension on repeated readings (systolic blood pressure > 180 mm Hg or diastolic blood pressure >105 mmHg). This can be treated, and blood pressure must be stable before venous access is obtained (systolic blood pressure < 150 mmHg, diastolic blood pressure < 100 mm Hg).

15. Pregnant or breastfeeding or plans to become pregnant in the next 12 months.

16. Thrombus of the inferior vena cava (IVC) extending at least one centimeter above the common iliac vein confluence.

17. Inability to obtain venous access.

18. Contraindication to Enoxaparin (e.g., Severe chronic kidney injury, allergic reaction, HIT)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 89 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Paul J. Gagne

OTHER

Sponsor Role: lead

Responsible Party

Paul J. Gagne

President, Vascular Breakthroughs, LLC

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Vascular Care Connecticut

Darien, Connecticut, United States

The Vascular Care Group

Hyannis, Massachusetts, United States

The Vascular Care Group

Leominster, Massachusetts, United States

The Vascular Care Group

Plymouth, Massachusetts, United States

The Vascular Care Group

Wellesley, Massachusetts, United States

The Vascular Care Group

Worcester, Massachusetts, United States

Countries

United States

Other Identifiers

CP-001

Identifier Type: -

Identifier Source: org_study_id